Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis. 2022

Pontus Plavén-Sigray, and Pauliina Ikonen Victorsson, and Alexander Santillo, and Granville J Matheson, and Maria Lee, and Karin Collste, and Helena Fatouros-Bergman, and Carl M Sellgren, and Sophie Erhardt, and Ingrid Agartz, and Christer Halldin, and Lars Farde, and Simon Cervenka
Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.

Pharmacological and genetic evidence support a role for an involvement of the dopamine D2-receptor (D2-R) in the pathophysiology of schizophrenia. Previous molecular imaging studies have suggested lower levels of D2-R in thalamus, but results are inconclusive. The objective of the present study was to use improved methodology to compare D2-R density in whole thalamus and thalamic subregions between first-episode psychosis patients and healthy controls. Differences in thalamocortical connectivity was explored based on the D2-R results. 19 antipsychotic-naive first-episode psychosis patients and 19 age- and sex-matched healthy controls were examined using high-resolution Positron Emission Tomography (PET) and the high-affinity D2-R radioligand [11C]FLB457. The main outcome was D2-R binding potential (BPND) in thalamus, and it was predicted that patients would have lower binding. Diffusion tensor imaging (DTI) was performed in a subgroup of 11 patients and 15 controls. D2-R binding in whole thalamus was lower in patients compared with controls (Cohen's dz = -0.479, p = 0.026, Bayes Factor (BF) > 4). Among subregions, lower BPND was observed in the ROI representing thalamic connectivity to the frontal cortex (Cohen's dz = -0.527, p = 0.017, BF > 6). A meta-analysis, including the sample of this study, confirmed significantly lower thalamic D2-R availability in patients. Exploratory analyses suggested that patients had lower fractional anisotropy values compared with controls (Cohen's d = -0.692, p = 0.036) in the inferior thalamic radiation. The findings support the hypothesis of a dysregulation of thalamic dopaminergic neurotransmission in schizophrenia, and it is hypothesized that this could underlie a disturbance of thalamocortical connectivity.

UI MeSH Term Description Entries
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001499 Bayes Theorem A theorem in probability theory named for Thomas Bayes (1702-1761). In epidemiology, it is used to obtain the probability of disease in a group of people with some characteristic on the basis of the overall rate of that disease and of the likelihood of that characteristic in healthy and diseased individuals. The most familiar application is in clinical decision analysis where it is used for estimating the probability of a particular diagnosis given the appearance of some symptoms or test result. Bayesian Analysis,Bayesian Estimation,Bayesian Forecast,Bayesian Method,Bayesian Prediction,Analysis, Bayesian,Bayesian Approach,Approach, Bayesian,Approachs, Bayesian,Bayesian Approachs,Estimation, Bayesian,Forecast, Bayesian,Method, Bayesian,Prediction, Bayesian,Theorem, Bayes
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D013788 Thalamus Paired bodies containing mostly GRAY MATTER and forming part of the lateral wall of the THIRD VENTRICLE of the brain. Thalamencephalon,Thalamencephalons
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D049268 Positron-Emission Tomography An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower. PET Imaging,PET Scan,Positron-Emission Tomography Imaging,Tomography, Positron-Emission,Imaging, PET,Imaging, Positron-Emission Tomography,PET Imagings,PET Scans,Positron Emission Tomography,Positron Emission Tomography Imaging,Positron-Emission Tomography Imagings,Scan, PET,Tomography Imaging, Positron-Emission,Tomography, Positron Emission
D050637 Receptors, Dopamine D3 A subtype of dopamine D2 receptors that are highly expressed in the LIMBIC SYSTEM of the brain. Dopamine D3 Receptors,Dopamine D3 Receptor,Dopamine Receptor D3,Receptor, Dopamine-D3,Dopamine-D3 Receptor
D056324 Diffusion Tensor Imaging The use of diffusion ANISOTROPY data from diffusion magnetic resonance imaging results to construct images based on the direction of the faster diffusing molecules. Diffusion Tractography,DTI MRI,Diffusion Tensor MRI,Diffusion Tensor Magnetic Resonance Imaging,Diffusion Tensor MRIs,Imaging, Diffusion Tensor,MRI, Diffusion Tensor,Tractography, Diffusion

Related Publications

Pontus Plavén-Sigray, and Pauliina Ikonen Victorsson, and Alexander Santillo, and Granville J Matheson, and Maria Lee, and Karin Collste, and Helena Fatouros-Bergman, and Carl M Sellgren, and Sophie Erhardt, and Ingrid Agartz, and Christer Halldin, and Lars Farde, and Simon Cervenka
July 2019, The international journal of neuropsychopharmacology,
Pontus Plavén-Sigray, and Pauliina Ikonen Victorsson, and Alexander Santillo, and Granville J Matheson, and Maria Lee, and Karin Collste, and Helena Fatouros-Bergman, and Carl M Sellgren, and Sophie Erhardt, and Ingrid Agartz, and Christer Halldin, and Lars Farde, and Simon Cervenka
December 2013, Psychological medicine,
Pontus Plavén-Sigray, and Pauliina Ikonen Victorsson, and Alexander Santillo, and Granville J Matheson, and Maria Lee, and Karin Collste, and Helena Fatouros-Bergman, and Carl M Sellgren, and Sophie Erhardt, and Ingrid Agartz, and Christer Halldin, and Lars Farde, and Simon Cervenka
June 2005, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
Pontus Plavén-Sigray, and Pauliina Ikonen Victorsson, and Alexander Santillo, and Granville J Matheson, and Maria Lee, and Karin Collste, and Helena Fatouros-Bergman, and Carl M Sellgren, and Sophie Erhardt, and Ingrid Agartz, and Christer Halldin, and Lars Farde, and Simon Cervenka
December 2014, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Pontus Plavén-Sigray, and Pauliina Ikonen Victorsson, and Alexander Santillo, and Granville J Matheson, and Maria Lee, and Karin Collste, and Helena Fatouros-Bergman, and Carl M Sellgren, and Sophie Erhardt, and Ingrid Agartz, and Christer Halldin, and Lars Farde, and Simon Cervenka
January 2010, Archives of general psychiatry,
Pontus Plavén-Sigray, and Pauliina Ikonen Victorsson, and Alexander Santillo, and Granville J Matheson, and Maria Lee, and Karin Collste, and Helena Fatouros-Bergman, and Carl M Sellgren, and Sophie Erhardt, and Ingrid Agartz, and Christer Halldin, and Lars Farde, and Simon Cervenka
May 2024, JAMA psychiatry,
Pontus Plavén-Sigray, and Pauliina Ikonen Victorsson, and Alexander Santillo, and Granville J Matheson, and Maria Lee, and Karin Collste, and Helena Fatouros-Bergman, and Carl M Sellgren, and Sophie Erhardt, and Ingrid Agartz, and Christer Halldin, and Lars Farde, and Simon Cervenka
December 2017, Schizophrenia research,
Pontus Plavén-Sigray, and Pauliina Ikonen Victorsson, and Alexander Santillo, and Granville J Matheson, and Maria Lee, and Karin Collste, and Helena Fatouros-Bergman, and Carl M Sellgren, and Sophie Erhardt, and Ingrid Agartz, and Christer Halldin, and Lars Farde, and Simon Cervenka
November 2012, Biological psychiatry,
Pontus Plavén-Sigray, and Pauliina Ikonen Victorsson, and Alexander Santillo, and Granville J Matheson, and Maria Lee, and Karin Collste, and Helena Fatouros-Bergman, and Carl M Sellgren, and Sophie Erhardt, and Ingrid Agartz, and Christer Halldin, and Lars Farde, and Simon Cervenka
December 2017, Schizophrenia research,
Pontus Plavén-Sigray, and Pauliina Ikonen Victorsson, and Alexander Santillo, and Granville J Matheson, and Maria Lee, and Karin Collste, and Helena Fatouros-Bergman, and Carl M Sellgren, and Sophie Erhardt, and Ingrid Agartz, and Christer Halldin, and Lars Farde, and Simon Cervenka
December 2003, The American journal of psychiatry,
Copied contents to your clipboard!